Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Lobular Breast Carcinoma|ER+ Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Entrectinib|DRUG: Letrozole|DRUG: Goserelin
Sponsor: Jules Bordet Institute
Collaborators: Hoffmann-La Roche